OncoMatch/Clinical Trials/NCT06540729
RC48 in Combination With AK104 and Bevacizumab in OCCC
Is NCT06540729 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer for ovary cancer.
Treatment: Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer — Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: HER2 (ERBB2) ihc ≥1+ (ihc ≥1+)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
white blood cell count ≥3.0×10^9/l, neutrophil count ≥1.5×10^9/l, platelet count ≥100×10^9/l, hemoglobin ≥80 g/l
Kidney function
creatinine ≤1.5× uln
Liver function
ast ≤2.5× uln, alt ≤2.5× uln, serum total bilirubin ≤1.5× uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06540729 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 ihc ≥1+ is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages